top of page
Browse by category
Search


GLP-1 receptor agonists target fat over muscle for weight loss
A research team from the School of Public Health, in the LKS Faculty of Medicine of the University of Hong Kong (HKUMed), who assessed...


CMS approves new quality measure tied to GLP-1 use and pulmonary aspiration
The Centers for Medicare & Medicaid Services (CMS) formally approved a new quality measure developed by the Quality Team at North...

Jiangsu and Kailera report positive topline data for 8mg HRS9531 GLP-1/GIP
Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics have announced positive topline data from the 8mg dose of Hengrui Pharma’s Phase...


GLP-1 drugs reduce surgery complications in patients with diabetes
People with diabetes who were taking GLP-1 receptor agonist drugs such as tirzepatide and semaglutide had significantly lower rates of...


Survey finds 93.4% of bariatric patients vs 51.4% of GLP-1 patients have the same treatment again
Over 93% of bariatric patients said they would undergo bariatric surgery again, compared with just over half of those who said they would...


More than half of US adults could benefit from GLP-1 medications
More than half of US adults, an estimated that 137 million people, are eligible for semagludtide for weight loss, diabetes management, or...


GLP-1 RAs found to shrink heart muscle in mice and human cells
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may be associated with shrinking the human heart and other muscles, according to a...

GLP-1 RAs show cardiovascular benefits beyond weight loss
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) continue to show cardiovascular benefits beyond weight loss, according to several...


GLP-1 RAs may be effective in helping people drink less alcohol
A study led by researchers at the University of Nottingham has found that glucagon-like peptide-1 receptor agonists use (GLP-1 RAs) may...


GLP-1s associated with higher risk of major depression, increased risk for anxiety and an elevated risk for suicidal behaviour
Patients on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) - Victoza (Liraglutide 1.8mg), Saxenda (Liraglutide 3mg), Ozempic...
Browse by tag






bottom of page